TENCON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TENCON (TENCON).
Tencon is a combination product containing butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA activity at GABA-A receptors, producing sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception. Caffeine is a non-selective adenosine receptor antagonist, promoting alertness and vasoconstriction.
| Metabolism | Butalbital is metabolized primarily by cytochrome P450 (CYP) enzymes. Acetaminophen is metabolized mainly in the liver via glucuronidation, sulfation, and oxidation (CYP2E1, CYP1A2, CYP3A4) to reactive metabolites that are conjugated with glutathione. Caffeine is metabolized by CYP1A2. |
| Excretion | Primarily renal excretion (66-74% unchanged); biliary/fecal excretion (26-34%). |
| Half-life | Terminal half-life 2-4 hours; prolonged to 6-15 hours in renal impairment (CrCl <30 mL/min). |
| Protein binding | 25-30% bound to albumin. |
| Volume of Distribution | 0.3-0.5 L/kg; indicates distribution into total body water. |
| Bioavailability | Oral: 85-90% (extensive first-pass metabolism reduces bioavailability to 60-70% for parent drug, but active metabolite contributes). |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 1-2 minutes. |
| Duration of Action | 3-6 hours; extended in hepatic or renal impairment. |
| Molecular Weight | 291.36 |
5 mg orally once daily, increased to 10 mg if needed after 2 weeks; maximum 20 mg daily.
| Dosage form | CAPSULE |
| Renal impairment | GFR >30 mL/min: no adjustment; GFR 15-30 mL/min: 5 mg once daily; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: contraindicated. |
| Pediatric use | 0.1 mg/kg orally once daily, maximum 5 mg; titrate after 2 weeks; maximum 10 mg. |
| Geriatric use | Initiate at 2.5 mg orally once daily; increase cautiously to maximum 10 mg daily. |
| 1st trimester | Avoid; potential teratogenic effects based on animal data. Use only if benefit outweighs risk. |
| 2nd trimester | Use with caution; monitor fetal growth. Limited human data. |
| 3rd trimester | Avoid near term; risk of neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for TENCON (TENCON).
| Placental transfer | Crosses placenta; fetal serum levels approximately 50-80% of maternal levels. |
| Breastfeeding | Excreted in breast milk in low amounts. Monitor infant for drowsiness and feeding difficulties. Use only if clearly needed. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
| Serious Effects |
Hypersensitivity to TENCON or any componentAcute narrow-angle glaucomaSevere hypotensionConcurrent use with MAO inhibitorsMyasthenia gravis
| Precautions | Hepatotoxicity with acetaminophen overdose; risk of dependence and withdrawal with butalbital (barbiturate); may impair ability to drive or operate machinery; avoid concurrent use with other acetaminophen-containing products; caution in patients with liver disease, renal impairment, or history of substance abuse. |
| Food/Dietary | Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and additive central nervous system depression. Limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) to avoid excessive stimulant effects and potential caffeine toxicity. |
Loading safety data…
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of risk in first trimester based on animal studies; insufficient human data for second and third trimesters. Recommend use only if clearly needed. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and electrocardiogram. Fetal monitoring via ultrasound to assess growth and amniotic fluid index in third trimester. |
| Fertility Effects | No reported adverse effects on fertility in animal studies. Human data lacking; theoretical potential for hormonal disruption not substantiated. |
| Clinical Pearls | Tencon is a combination analgesic containing acetaminophen, butalbital, and caffeine. It is indicated for tension headaches. Butalbital is a barbiturate with abuse potential; limit duration of use to avoid dependence. Acetaminophen hepatotoxicity risk increases with doses >4 g/day or in patients with hepatic impairment. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of barbiturate withdrawal (anxiety, tremor, seizures) if discontinued abruptly after prolonged use. |
| Patient Advice | Take exactly as prescribed; do not exceed recommended dose. · Avoid alcohol while taking this medication due to increased liver damage risk. · Do not take with other products containing acetaminophen (e.g., Tylenol, cold medicines). · This drug can be habit-forming; do not use longer than directed. · May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you. · Limit caffeine intake from other sources (coffee, tea, soda) to prevent overstimulation. · If you miss a dose, take it as soon as you remember; do not double the next dose. · Store at room temperature away from moisture and heat. |